Liposomal Sulforaphane Supplement Manufacturer | Private Label, OEM & Bulk Supply

SFN, glucoraphanin, myrosinase-containing systems, and broccoli sprout extracts are not interchangeable. The active foundation affects formulation, stability, testing, dosage communication, and product positioning.

Important: a GR-based product should not automatically be described as a liposomal sulforaphane product. The final product description should accurately reflect the active system and manufacturing configuration.

Related internal Resource: Sulforaphane vs. Glucoraphanin

During liposomal sulforaphane formulation development, the following parameters can be evaluated and customized:

• Active system and active loading per serving
• Sunflower-derived or soy-derived phosphatidylcholine
• Phospholipid-to-active ratio
• Particle-size and PDI development targets
• Encapsulation-efficiency target based on the formulation
• Serving size and capsule fill weight
• HPMC or gelatin capsule shell
• Capsule size, color, and appearance
• Powder, capsule, liquid, or bulk format
• Packaging configuration and moisture protection
• Desiccant strategy and barrier packaging
• Target market and applicable product specification

Higher active loading is not automatically better. The formulation must balance active dose, carrier ratio, particle-size distribution, powder properties, stability, capsule capacity, and commercial cost.

Liposomal delivery can make sulforaphane an attractive option for brands developing premium supplement products around antioxidant, cellular wellness, and healthy-aging positioning. The formulation value of a liposomal system is primarily related to delivery-system design, ingredient protection, and product differentiation rather than simply adding another active to the formula.

From a product-development perspective, key considerations include:

• Premium positioning: A liposomal delivery system can provide a differentiated formulation story compared with conventional sulforaphane products.
• Delivery-focused formulation: Phospholipid-based systems can be engineered around particle size, encapsulation efficiency, and physical stability.
• Flexible product development: Liposomal SFN can be developed as a single-active product or combined with selected ingredients for broader formulation concepts.
• Commercial differentiation: Delivery technology can help brands create a more specialized product architecture beyond standard sulforaphane capsules.

The final formulation should be evaluated based on the active form, target dose, delivery system, stability requirements, dosage form, and target market.

Capsules offer a practical commercial format for liposomal sulforaphane, combining convenient dosing, dry-state storage, and efficient global shipping. For B2B product development, the key is not simply filling liposomal powder into a capsule—it is ensuring that the active dose, powder characteristics, capsule capacity, stability, and target cost work together.

Capsule Development Focus

• Dose & Fill Weight: Target active dose is matched with powder assay, bulk density, and capsule capacity to determine a commercially feasible fill weight.
• Powder Performance: Density, flowability, moisture sensitivity, and particle characteristics are evaluated before encapsulation.
• Capsule Selection: HPMC or gelatin shells can be selected according to product positioning, market requirements, and formulation compatibility.
• Moisture & Stability: Controlled-humidity processing and moisture-barrier packaging can be considered where required by the formulation and stability profile.
• Quality Control: Finished capsules can be evaluated for active assay, dosage uniformity, microbiological quality, and applicable physical specifications.

Capsule Size & Dose Feasibility

Common capsule sizes include #0, #00, and #1, but capsule selection should not be based on size alone.

The actual fill weight depends on:

Target SFN Dose → Powder Assay → Bulk Density → Formula Composition → Capsule Capacity

If the target dose cannot be accommodated in the preferred capsule size, the formulation can be reviewed through dose adjustment, excipient optimization, capsule-size selection, or serving-size adjustment.

This feasibility assessment helps brands avoid developing a formula that looks attractive on paper but is difficult to manufacture at commercial scale.

From Formula Concept to Commercial Capsule

Already have a target SFN dose or formula?

KS Nutripharma can evaluate the formulation for capsule capacity, powder handling, stability, packaging, and commercial manufacturing feasibility before finalizing the production specification.

[Explore Sulforaphane Capsule Supplement Manufacturing →]

[Request a Capsule Formulation Assessment →]

Quality testing is defined around the active system, dosage form, product specification, and target market. For liposomal sulforaphane, the focus is not only on finished-product assay, but also on raw-material identity, delivery-system characteristics, and stability over time.

Stability Approach

Stability testing is designed around the specific formulation and its known degradation risks.

Depending on the product architecture, the study may monitor:

• Active stability: changes in SFN or other specified actives
• Delivery-system stability: particle size, PDI, and encapsulation efficiency where applicable
• Lipid stability: oxidation-related indicators for phospholipid-containing systems
• Physical stability: moisture and relevant dosage-form characteristics
• Microbiological stability: microbiological parameters according to the product specification

Real-time and accelerated studies can be conducted according to the agreed stability protocol, product specification, and target-market requirements.

Documentation Available for Review

Depending on project scope and confidentiality requirements, buyers may request:

• Product specifications
• Batch-specific CoA
• Applicable analytical methods or method references
• Stability study summaries
• Relevant batch and quality documentation

The specific testing panel is agreed during product development rather than applying the same QC package to every sulforaphane formulation.

Choose the collaboration model that matches your current sulforaphane liposomal development stage.

Have a validated formula? → OEM
Need formulation engineering? → ODM
Looking for a faster launch? → Explore Private Label options

A structured development process helps move a liposomal sulforaphane concept from initial requirements to repeat commercial production.

1. Requirement Review

Confirm the active system, target dose, dosage form, target market, packaging, and expected volume.

2. Feasibility Assessment

Review formulation fit, dosage-form feasibility, processing requirements, stability considerations, and target cost.

3. Sample Development

Develop the prototype and conduct the agreed analytical and formulation evaluations.

4. Pilot Validation

Validate the manufacturing process, scale-up parameters, and batch consistency before commercial production.

5. Commercial Production

Manufacture the approved formula with QC testing, packaging, documentation, and batch release.

6. Ongoing Supply

Support repeat production, quality monitoring, production scheduling, and supply planning.

Timeline depends on formulation complexity, analytical requirements, packaging, and specification approval. A technical feasibility assessment is completed before commercial production is scheduled.

Typical starting points are provided below for initial project planning. Actual MOQ and lead time depend on the formulation, dosage form, packaging, testing requirements, and production schedule.

For recurring programs, production scheduling can be planned around annual demand, forecast volume, lead-time requirements, and inventory strategy.

Need a project-specific MOQ or lead-time estimate? Include your target quantity and packaging requirements in the RFQ.